Table 1. Baseline Demographics and Characteristics (Intent-to-Treat Population).
| Characteristic | Participants, No. (%) | ||
|---|---|---|---|
| Xanomeline-trospium chloride (n = 125) | Placebo (n = 131) | Overall (N = 256) | |
| Age, mean (SD), y | 43.6 (11.4) | 42.6 (12.2) | 43.1 (11.8) |
| Sex | |||
| Female | 38 (30.4) | 27 (20.6) | 65 (25.4) |
| Male | 87 (69.6) | 104 (79.4) | 191 (74.6) |
| Race | |||
| Asian | 1 (0.8) | 0 | 1 (0.4) |
| Black or African American | 79 (63.2) | 77 (58.8) | 156 (60.9) |
| White | 45 (36.0) | 53 (40.5) | 98 (38.3) |
| Not reported | 0 | 1 (0.8) | 1 (0.4) |
| Body mass index, mean (SD)a | 28.8 (5.6) | 28.0 (5.2) | 28.38 (5.4) |
| Baseline PANSS score, mean (SD) | |||
| Total | 97.3 (8.9) | 96.7 (8.9) | 97.0 (8.9) |
| Positive subscale score | 26.9 (3.7) | 26.4 (3.3) | 26.7 (3.5) |
| Negative subscale score | 22.6 (3.2) | 22.0 (3.7) | 22.3 (3.5) |
| Marder negative factor score | 22.0 (3.7) | 21.8 (4.2) | 21.9 (3.9) |
| Baseline CGI-S score, mean (SD) | 5.1 (0.6) | 5.0 (0.6) | 5.1 (0.6) |
Abbreviations: CGI-S, Clinical Global Improvement–Severity; PANSS, Positive and Negative Syndrome Scale.
a
Body mass index is calculated as weight in kilograms divided by height in meters squared.